Citius Pharmaceuticals
CTXR
40 hedge funds and large institutions have $1.35M invested in Citius Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.
1,353% more capital inflows, than outflows
Capital inflows: $1.49M | Capital outflows: $102K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
14% more funds holding
Funds holding: 35 → 40 (+5)
4.65% more ownership
Funds ownership: 3.72% → 8.37% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Heights Capital Management
San Francisco,
California
|
+$1M |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
+$114K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$63.2K |
| 4 |
Two Sigma Investments
New York
|
+$48.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.1K |
| 2 |
NewEdge Advisors
New Orleans,
Louisiana
|
-$31.3K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$12K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$11K |
| 5 |
Jane Street
New York
|
-$1.16K |
CTXR Hedge Fund Activity: Q4 2025 in Review
40 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2025, worth a combined $1.35M — up 72% from $784K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CTXR positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Heights Capital Management, opening a new position worth an estimated $1M. The largest seller was Susquehanna International Group, cutting an estimated $44.1K.
- 40 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2025, up from 35 in Q3 2025.
- Funds reported $1.35M of Citius Pharmaceuticals stock for Q4 2025, up 72% quarter-over-quarter.
- 9 funds opened new Citius Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +5 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2025 was Heights Capital Management, an estimated $1M added.
- The largest Citius Pharmaceuticals seller in Q4 2025 was Susquehanna International Group, an estimated $44.1K sold.
Based on aggregated 13F filings for Q4 2025.